145.21
前日終値:
$144.99
開ける:
$144.23
24時間の取引高:
3.70M
Relative Volume:
0.52
時価総額:
$180.27B
収益:
$29.45B
当期純損益:
$8.51B
株価収益率:
21.41
EPS:
6.7823
ネットキャッシュフロー:
$9.46B
1週間 パフォーマンス:
-0.97%
1か月 パフォーマンス:
-6.30%
6か月 パフォーマンス:
+30.99%
1年 パフォーマンス:
+30.30%
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, AZN, NVS
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
GILD
Gilead Sciences Inc
|
145.21 | 180.27B | 29.45B | 8.51B | 9.46B | 6.7823 |
|
LLY
Lilly Eli Co
|
989.12 | 883.28B | 65.18B | 20.64B | 5.96B | 22.59 |
|
JNJ
Johnson Johnson
|
243.19 | 586.06B | 94.19B | 26.80B | 19.70B | 11.05 |
|
ABBV
Abbvie Inc
|
221.45 | 391.56B | 61.16B | 4.19B | 17.82B | 2.3614 |
|
AZN
Astrazeneca Plc
|
192.01 | 297.77B | 58.80B | 10.24B | 8.98B | 3.2788 |
|
NVS
Novartis Ag Adr
|
154.87 | 295.52B | 54.72B | 14.02B | 15.32B | 7.1855 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-10 | 開始されました | Jefferies | Buy |
| 2026-02-20 | 開始されました | Barclays | Equal Weight |
| 2026-02-11 | 繰り返されました | Needham | Buy |
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
CSM Advisors LLC Sells 42,400 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
This $64 Million Biotech Exit Seemingly Missed a 77% One-Day Surge on Gilead Takeover Deal - The Motley Fool
Gilead Sciences, Inc. (NASDAQ:GILD) Short Interest Down 15.7% in February - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Holocene Advisors LP - MarketBeat
Gotham Asset Management LLC Has $38.40 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Crawford Investment Counsel Inc. Decreases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. (GILD): Growth Prospects Backed by Analyst Upgrades - Insider Monkey
Capitolis Liquid Global Markets LLC Invests $40.40 Million in Gilead Sciences, Inc. $GILD - MarketBeat
Calydon Capital Has $7.34 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Chevy Chase Trust Holdings LLC Has $70.93 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
California Public Employees Retirement System Has $447.80 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
BNP Paribas Has $7.71 Million Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Banco Bilbao Vizcaya Argentaria S.A. Grows Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Ameriprise Financial Inc. Buys 400,002 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Alliancebernstein L.P. Sells 258,213 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences to buy Arcellx in deal valued at $7.8 billion - MSN
Wellington Management Group LLP Has $2.84 Billion Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by Prudential PLC - MarketBeat
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oruka Therapeutics (ORKA), Radnet (RDNT) and Gilead Sciences (GILD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Korro Bio (KRRO), Oruka Therapeutics (ORKA) and Gilead Sciences (GILD) - The Globe and Mail
Dodge & Cox Trims Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (NASDAQ:GILD) Upgraded at Wall Street Zen - MarketBeat
Precision Trading with Gilead Sciences Inc. (GILD) Risk Zones - Stock Traders Daily
'Manufacturing is access': How Gilead's early production moves set PrEP med Yeztugo up for success - Fierce Pharma
Analysts Set Expectations for Gilead Sciences Q1 Earnings - MarketBeat
Martingale Asset Management L P Decreases Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Invesco Ltd. Purchases 1,618,453 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
The Zacks Analyst Blog Oracle, T-Mobile, Gilead, and C&F Financial - Yahoo Finance Singapore
How Renewed Wall Street Optimism Around HIV, Oncology And IP Runway At Gilead Sciences (GILD) Has Changed Its Investment Story - finance.yahoo.com
[Form 4] GILEAD SCIENCES, INC. Insider Trading Activity - Stock Titan
Stock Traders Purchase Large Volume of Call Options on Gilead Sciences (NASDAQ:GILD) - MarketBeat
HIV prevention efforts amplified through music at SXSW, Gilead Sciences asserts - Traders Union
Assessing Gilead Sciences (GILD) Valuation After Recent Share Price Momentum And Mixed Fair Value Signals - simplywall.st
Gilead Sciences, Inc. $GILD Stake Boosted by SageView Advisory Group LLC - MarketBeat
Franklin Resources Inc. Decreases Stake in Gilead Sciences, Inc. $GILD - MarketBeat
Bokf Na Raises Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead (NASDAQ:GILD) Institutional Focus Rises In Nasdaq 100 Index - Kalkine Media
HER2-Negative Metastatic Breast Cancer Market Expected to Transform Significantly Through 2034, According to DelveInsight | Genentech, AstraZeneca, Merck Sharp & Dohme LLC, Gilead Sciences, BeiGene - StreetInsider
Gilead Sciences at Barclays Conference: Strategic Growth and Diversification - Investing.com
News | British Land and Royal London sign Gilead at Euston development - CoStar
Gilead’s US$7.8b Arcellx Deal Deepens Cell Therapy Diversification - simplywall.st
Gilead Sciences, Inc. $GILD Shares Sold by Mackenzie Financial Corp - MarketBeat
Magnetar Financial LLC Increases Stock Position in Gilead Sciences, Inc. $GILD - MarketBeat
British Land and Royal London Asset Management announce letting to Gilead Sciences at One Triton Square, Regent’s Place - British Land
GILD Stock Price, Quote & Chart | GILEAD SCIENCES INC (NASDAQ:GILD) - ChartMill
Gilead at Leerink Conference: Strategic Expansion in Healthcare - Investing.com India
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street’s Latest Biopharma Calls Explained - AOL.com
Jefferies Initiates Coverage on Gilead Sciences (GILD) with 'Buy' Rating | GILD Stock News - GuruFocus
Gilead Gets a Buy, Amgen a Hold and ORIC a Vote of Confidence: Wall Street's Latest Biopharma Calls Explained - 24/7 Wall St.
What 16 Analyst Ratings Have To Say About Gilead Sciences - Benzinga
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):